RxDoctor Payments Data

Jason Leader, PA

Physician Assistant · Pembroke Pines, FLNPI 1841529591

Payments from drug & device makers

$6,893in general payments, 2019–2025

Across 345 payments — averaging $19.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$841
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$626
  • Madrigal Pharmaceuticals$462
  • Ipsen Biopharmaceuticals, Inc$389
  • QOL Medical, LLC$318
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$6,77498%
  • Education$1192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,893 in reported general payments places this provider in the 90th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$18,070
Medicare patients
46
Services billed
264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab13$356,941
LinzessLinaclotide105$77,344
ClenpiqSod Picosulf/Mag Ox/Citric Ac173$29,371
VemlidyTenofovir Alafenamide12$16,953
Mesalamine12$4,068
CholestyramineCholestyramine (With Sugar)28$1,948
Pantoprazole Sodium215$1,771
Lubiprostone19$1,670
Lactulose35$1,529
Sucralfate43$1,470
Balsalazide Disodium15$969
Esomeprazole Magnesium17$928
Dicyclomine Hcl59$859
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl52$796
Famotidine90$728

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$841$356,94113 claims
AbbVieLinzess$1,885$77,344105 claims
GileadVemlidy$168$16,95312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →